Century Therapeutics executive sells 534 shares for taxes

Century Therapeutics, Inc. (IPSC) reported that Chief Technology and Manufacturing Officer Gregory Russotti sold 534 shares of common stock on September 8, 2026 at $2.05 per share.

Rhea-AI Filing Summary

Century Therapeutics, Inc. (IPSC) reported that Chief Technology and Manufacturing Officer Gregory Russotti sold 534 shares of common stock on September 8, 2026 at $2.05 per share. A footnote states these shares were sold automatically to cover tax withholding obligations related to vesting restricted stock units and not at his discretion.

After this transaction, Russotti held 511,785 shares of Century Therapeutics common stock directly and 92,773 shares indirectly through the Gregory Russotti 2021 Family Trust. No Rule 10b5-1 trading plan is reported for these transactions.

Insider Trade Summary

Net Seller: 534 shares

Net Sell 2 txns

Insider Russotti Gregory

Role See Remarks

Sold 534 shs ($1K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	534	$2.05	$1K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 511,785 shares (Direct); Common Stock — 92,773 shares (Indirect, By Gregory Russotti 2021 Family Trust)

Footnotes (1)

1. F1. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

Key Figures

Shares sold: 534 shares Sale price per share: $2.05 per share Direct holdings after transaction: 511,785 shares +2 more

5 metrics

Shares sold 534 shares Automatic sale on September 8, 2026 to cover tax withholding

Sale price per share $2.05 per share Common stock sale on September 8, 2026

Direct holdings after transaction 511,785 shares Century Therapeutics common stock held directly by Gregory Russotti after the sale

Indirect holdings after transaction 92,773 shares Common stock held indirectly through the Gregory Russotti 2021 Family Trust

Net shares sold 534 shares Net sell direction across reported non-derivative transactions

Key Terms

restricted stock units, tax withholding obligations, indirect, Family Trust

4 terms

restricted stock units financial

"in connection with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"shares required to be sold ... to cover tax withholding obligations"

indirect financial

"Indirect ownership: By Gregory Russotti 2021 Family Trust"

Family Trust financial

"By Gregory Russotti 2021 Family Trust"

FAQ

What insider transaction did IPSC report for Gregory Russotti on September 8, 2026?

Century Therapeutics reported that 534 shares of common stock were sold on September 8, 2026 at $2.05 per share, in a transaction attributed to Chief Technology and Manufacturing Officer Gregory Russotti.

Why were Gregory Russotti’s IPSC shares sold in this Form 4 filing?

The filing states the 534 shares were sold to cover tax withholding obligations triggered by the vesting of restricted stock units, and that the sales were automatic and not at the discretion of Gregory Russotti.

How many IPSC shares does Gregory Russotti hold after this reported sale?

After the transaction, Gregory Russotti held 511,785 IPSC shares directly and 92,773 IPSC shares indirectly through the Gregory Russotti 2021 Family Trust, according to the filing.

Was a Rule 10b5-1 trading plan used for Gregory Russotti’s IPSC share sale?

No. The document-level checkbox for Rule 10b5-1 is marked false, and the footnote only describes an automatic sale for tax withholding in connection with RSU vesting, not a pre-arranged trading plan.

What is Gregory Russotti’s role at Century Therapeutics (IPSC) mentioned in this filing?

The filing identifies Gregory Russotti as Century Therapeutics’ Chief Technology and Manufacturing Officer, as noted in the remarks section accompanying the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/09/2026 - 04:37 PM Accepted by SEC EDGAR 09/09/2026 - 04:35 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Russotti Gregory

(Last) (First) (Middle)

C/O CENTURY THERAPEUTICS, INC.

25 N 38TH STREET, 12TH FLOOR

(Street)

PHILADELPHIA PENNSYLVANIA 19104

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Century Therapeutics, Inc. [ IPSC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/08/2026		S(1)		534	D	$2.05	511,785	D
Common Stock								92,773	I	By Gregory Russotti 2021 Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

Remarks:

Title: Chief Technology and Manufacturing Officer

	/s/ Douglas Carr, Attorney-in-Fact	09/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)